Imerys (NK) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
3 Feb, 2026Opening remarks and agenda
The meeting was chaired by Patrick Kron, with executive presentations from Alessandro Dazza and Sébastien Rouge, and included safety instructions and a welcome, noting the meeting would be filmed and available online.
Legal formalities for convening the meeting were confirmed, with all required documents made available to shareholders.
The quorum was established at 92.5%, and voting procedures were explained.
The agenda covered 2024 results, Q1 2025 update, sustainability, dividend proposal, resolutions, auditor reports, Q&A, and voting.
Financial performance review
2024 revenue reached EUR 3.605 billion, with 1% organic growth and adjusted EBITDA up 11.4% to EUR 675 million; EBITDA margin improved to 18.7%.
Free cash flow before strategic investments was EUR 66 million; net debt at year-end was EUR 1.275 billion, with net debt/EBITDA at 1.9x and investment grade ratings confirmed.
Q1 2025 revenue was EUR 871 million (+0.7% like-for-like), with EBITDA at EUR 128 million, showing continued organic growth despite weak industrial markets.
Net current income from continuing operations was EUR 262 million (+8.2%).
Divestment of paper market assets impacted sales by EUR -182 million.
Board and executive committee updates
Board composition changes included the renewal of two directors and appointment of two new directors, maintaining 60% independence and 40% female representation.
Thanks were extended to outgoing board members and committee chairs for their contributions.
Latest events from Imerys
- Stable 2025 results, major goodwill impairment, and cost savings plus lithium investment ahead.NK
Q4 202520 Feb 2026 - H1 2024 adjusted EBITDA rose 11% to €384m, margin 20%, with strong cash flow and guidance.NK
H1 20242 Feb 2026 - Nine-month EBITDA margin rose to 19.2% as full-year guidance is confirmed.NK
Q3 202417 Jan 2026 - Organic growth and sustainability progress offset margin pressure from joint venture declines.NK
Q1 202524 Dec 2025 - Organic growth, margin expansion, and strong ESG progress with robust 2025 outlook.NK
H2 202415 Dec 2025 - Stable H1 2025 sales and EBITDA, but net income fell; full-year EBITDA guidance reaffirmed.NK
Q2 202516 Nov 2025 - Revenue down 0.7% YTD; cost controls and strategic growth moves support profitability.NK
Q3 20251 Nov 2025